Will the Phase 2 trial "Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States" reach primary completion on or before Aug 31, 2029?

Resolves Yes if ClinicalTrials.gov record NCT05832229 (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)) shows an actual primary completion date on or before Aug 31, 2029. Registered date at generation: Aug 31, 2029.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Aug 31, 2029, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.